LONDON, Jan. 16, 2017 /PRNewswire/ -- Ever since the establishment of the genetic basis of life, researchers have tried to manipulate genes in plants and animals to improve traits. There has been a continuous evolution of gene modification technique starting from restriction endonucleases, transgenic breeding, RNAi technologies to the current engineered endonucleases. Over the last several decades, technologies for identification, isolation, sequencing, replication and integration of desired genes in target organisms have transformed tremendously and emerged as one of the exciting and significant areas of scientific endeavour.
The Genome editing global market is segmented based on technology, applications, products, end users and geography. Technologies segment consists of Zinc Finger Nucleases (ZFN), Transcriptor-activator-like effector nuclease (TALEN); Clustered regularly interspaced short palindromic repeats (CRISPR) and other gene modification techniques such as Recombinant adeno-associated virus (rAAV), piggyBac transposon, megatales etc. Applications identified includes, basic research, agriculture biotechnology, animal research, drug discovery and development. Products are classified into reagents, enzymes and consumables, instruments, cell lines & animal models and software. Depending on the end users, the genome editing global market is sectioned into academic & government institutions, pharmaceutical & biotechnology companies, plant biotechnology and others.
This report studies the genome editing global market over the forecast period 2015 to 2022 and the market is expected to grow at high double digit CAGR to reach $2,669.9 million by 2022. Increased R&D expenditure and growth of biotechnology and pharmaceutical industries, increasing private and public sector funding, rapid advancements in sequencing and gene editing technologies, non-labeling of gene-edited products as Genetically Modified Organisms (GMOs), applications in various drug discovery processes are some of the factors driving the genome editing global market growth. Factors such as stringent regulatory framework, ethical issues concerning editing human embryo and adverse public perception, unavailability of gene-editing based therapeutics in the market, off-target effects of CRISPR and patent disputes associated with CRISPR technology are hampering the market growth.
Geographically, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. North America dominated the genome editing market with the largest share which is driven by factors such as increasing awareness of technology, proximity of companies, and early adoption of latest treatments. The Asian market is expected to occupy second place due increasing government funding of research, economic prosperity, early adoption of latest technology and the relaxed regulatory environment. The European market is expected to be third largest market, growing at a lower rate mainly due to the stringent regulatory environment and slow growth due to the economic crisis.
The genome editing global market is a consolidated market with key players such as Applied Stemcell (U.S.), Cellectis S.A. (France), Genscript (U.S.), Horizon Discovery Group (U.K.), Merck KGaA (Germany), Origene Technologies (U.S.), Sangamo Biosciences (U.S.), System Biosciences (U.S.), Thermo Fisher Scientific (U,S,), Transposagen (U.S.).
Download the full report: https://www.reportbuyer.com/product/4166819/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article